Journal
CLINICAL CANCER RESEARCH
Volume 27, Issue 17, Pages 4883-4897Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-21-0714
Keywords
-
Categories
Funding
- NCIAVON Partners for Progress Award [3P30CA06516-45S2]
- Tracey Davis Memorial Fund
- Rosanne's Rush for Research
- Boston Chapter of Golfers Against Cancer
- MGH Executive Committee on Research (ECOR) Research Scholar Award
- National Cancer Center
- MGH ECOR Fund for Medical Discovery
- MGH Cancer Center Excellence Award
Ask authors/readers for more resources
This study identifies high levels of RASAL2 as predictors of chemotherapy response and long-term outcomes in TNBC. RASAL2 rewires MAPK feedback and cross-talk to confer resistance to MEK1/2 and EGFR inhibitors while also indicating sensitivity to these inhibitors.
Purpose While chemotherapy remains the standard treatment for triple-negative breast cancer (TNBC), identifying and managing chemoresistant tumors has proven elusive. We sought to discover hallmarks and therapeutically actionable features of refractory TNBC through molecular analysis of primary chemoresistant TNBC specimens. Experimental Design: We performed transcriptional profiling of tumors from a phase II clinical trial of platinum chemotherapy for advanced TNBC (TBCRC-009), revealing a gene expression signature that identified de novo chemorefractory tumors. We then employed pharmacogenomic data mining, proteomic and other molecular studies to define the therapeutic vulnerabilities of these tumors. Results: We reveal the RAS-GTPase-activating protein (RAS-GAP) RASAL2 as an upregulated factor that mediates chemotherapy resistance but also an exquisite collateral sensitivity to combination MAP kinase kinase (MEK1/2) and EGFR inhibitors in TNBC. Mechanistically, RASAL2 GAP activity is required to confer kinase inhibitor sensitivity, as RASAL2-high TNBCs sustain basal RAS activity through suppression of negative feedback regulators SPRY1/2, together with EGFR upregulation. Consequently, RASAL2 expression results in failed feedback compensation upon co-inhibition of MEK1/2 and EGFR that induces synergistic apoptosis in vitro and in vivo. In patients with TNBC, high RASAL2 levels predict clinical chemotherapy response and long-term outcomes, and are associated via direct transcriptional regulation with activated oncogenic Yes-Associated Protein (YAP). Accordingly, chemorefractory patient-derived TNBC models exhibit YAP activation, high RASAL2 expression, and tumor regression in response to MEK/EGFR inhibitor combinations despite well-tolerated intermittent dosing. Conclusions: These findings identify RASAL2 as a mediator of TNBC chemorcsistance that rewires MAPK feedback and cross-talk to confer profound collateral sensitivity to combination MEK1/2 and EGFR inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available